Nano-encapsulated DNA and/or protein boost immunizations increase efficiency of DNA vaccine protection against RSV

Journal of Nanomedicine and Nanotechnology

Volumn 3, Issue 2, 2012, Pages

  Barnum, Seyhan Boyoglu ^b   Subbarayan, Praseetha ^a   Vig, Komal ^a   Pillai, Shreekumar ^a   Dennis, Vida A ^a   Singh, Shree R ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

^b Emory Children's Center   (United States)

Author keywords

Chitosan; DNA; Protein boost; RSV; Vaccine

Indexed keywords

EID: 84878063610     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000132     Document Type: Article

References (67)

1. Collins PL, Hill MG, Johnson PR (1990) The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J Gen Virol 71: 3015-3020.
2. Singh SR, Dennis VA, Carter CL, Pillai SR, Jefferson A, et al. (2007) Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25: 6211-6223.
3. Falsey AR, Walsh EE (1992) Humoral immunity to respiratory syncytial virus infection in the elderly. J Med Virol 36: 39-43.
4. Xu J, Ding Y, Yang Y (2008) Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome. Viral Immunol 21: 483-489.
5. Dudas RA, Karron RA (1998) Respiratory syncytial virus vaccines. Clin Microbiol Rev 11: 430-439.
6. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, et al. (1969) Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alumprecipitated respiratory syncytial virus vaccine. Am J Epidemiol 89: 435-448.
7. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89: 405-421.
8. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
9. Olson MR, Varga SM (2007) CD8 T cells inhibit respiratory syncytial virus (RSV) vaccineenhanced disease. J Immunol 179: 5415-5424.
10. Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, et al. (2009) Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine 5: 463-472.
11. Singh SR, Dennis VA, Carter CL, Pillai SR, Moore EG (2007) Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol 20: 261-275.
12. Lopez JA, Penas C, Garcia-Barreno B, Melero JA, Portela A (1990) Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J Virol 64: 927-930.
13. Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, et al. (1998) Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72: 6922-6928.
14. Bourgeois C, Corvaisier C, Bour JB, Kohli E, Pothier P (1991) Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J Gen Virol 72: 1051-1058.
15. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, et al. (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624.
16. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, et al. (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 83: 12601-12610.
17. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, et al. (2007) Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 25: 8782-8793.
18. Connors M, Kulkarni AB, Collins PL, Firestone CY, Holmes KL, et al. (1992) Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 66: 1277-1281.
19. Zeng R, Zhang Z, Mei X, Gong W, Wei L (2008) Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice. Biochem Biophys Res Commun 377: 495-499.
20. Mok H, Lee S, Wright DW, Crowe JE (2008) Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine 26: 4775-4782.
21. Heidema J, de Bree GJ, De Graaff PM, van Maren WW, Hoogerhout P et al. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 85: 2365-2374.
22. Vallbracht S, Jessen B, Mrusek S, Enders A, Collins PL, et al. (2007) Influence of a single viral epitope on T cell response and disease after infection of mice with respiratory syncytial virus. J Immunol 179: 8264-8273.
23. Lee S, Miller SA, Wright DW, Rock MT, Crowe JE, (2007) Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. J Virol 81: 2349-2358.
24. Zeng RH, Gong W, Fan CF, Wang YF, Mei XG (2006) Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope. Vaccine 24: 941-947.
25. Miller M, Cho JY, Baek KJ, Castaneda D, Nayar J, et al. (2002) Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsiveness. Vaccine 20: 3023-3033.
26. Li X, Sambhara S, Li CX, Ettorre L, Switzer I, et al. (2000) Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269: 54-65.
27. Oshansky CM, Barber JP, Crabtree J, Tripp RA (2010) Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 201: 1201-1207.
28. Power UF, Plotnicky H, Blaecke A, Nguyen TN (2003) The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine 22: 168-176.
29. Subbarayan P, Qin H, Pillai S, Lee JJ, Pfendt AP, et al. (2010) Expression and characterization of a multivalent human respiratory syncytial virus protein. Mol Biol (Mosk) 44: 477-487.
30. Gurunathan S, Wu CY, Freidag BL, Seder RA (2000) DNA vaccines: a key for inducing longterm cellular immunity. Curr Opin Immunol 12: 442-447.
31. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175: 633-639.
32. Xu K, Ling ZY, Sun L, Xu Y, Bian C, et al. (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 24: 45-56.
33. Hallengard D, Haller BK, Petersson S, Boberg A, Maltais AK, et al. (2011) Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29: 839-848.
34. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, et al. (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351: 1320-1325.
35. Wu H, Dennis VA, Pillai SR, Singh SR (2009) RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res 145: 39-47.
36. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51: 81-96.
37. Borchard G, Junginger HE (2001) Modern drug delivery applications of chitosan. Adv Drug Deliv Rev 52: 103.
38. Li GP, Liu ZG, Liao B, Zhong NS (2009) Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 6: 45-50.
39. Bozkir A, Saka OM (2004) Chitosan-DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency. J Drug Target 12: 281-288.
40. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, et al. (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70: 399-421.
41. Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5: 387-391.
42. Zhao F, Wang S, Zhang X, Gu W, Yu J, et al. (2012) Protective efficacy of a Treponema pallidum Gpd DNA vaccine vectored by chitosan nanoparticles and fused with interleukin-2. Can J Microbiol 58: 117-123.
43. Zhao K, Shi X, Zhao Y, Wei H, Sun Q, et al. (2011) Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29: 8549-8556.
44. Zhao F, Wu Y, Zhang X, Yu J, Gu W, et al. (2011) Enhanced immune response and protective efficacy of a Treponema pallidum Tp92 DNA vaccine vectored by chitosan nanoparticles and adjuvanted with IL-2. Hum Vaccin 7: 1083-1089.
45. Liu FP, Chang D, Yu YK, Zhang FC, Zhang AL (2012) [The efficacy of enhancing murine zona pellucid 3 DNA vaccine immunized through intranasal vaccination by IL-15]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28: 25-28.
46. Heuking S, Borchard G (2012) Toll-like receptor-7 agonist decoration enhances the adjuvanticity of chitosan-DNA nanoparticles. J Pharm Sci 101: 1166-1177.
47. Martinez X, Brandt C, Saddallah F, Tougne C, Barrios C, et al. (1997) DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc Natl Acad Sci U S A 94: 8726-8731.
48. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, et al. (2002) Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 14: 31-37.
49. Ma Z, Lim LY (2003) Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm Res 20: 1812-1819.
50. Letellier C, Boxus M, Rosar L, Toussaint JF, Walravens K, et al. (2008) Vaccination of calves using the BRSV nucleocapsid protein in a DNA primeprotein boost strategy stimulates cellmediated immunity and protects the lungs against BRSV replication and pathology. Vaccine 26: 4840-4848.
51. George JA, Eo SK (2011) Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2. Immune Netw 11: 268-280.
52. Han Y, Li Y, Song J, Wang Y, Shi Q, et al. (2011) Immune Responses in Wildtype Mice Against Prion Proteins Induced Using a DNA Prime-Protein Boost Strategy. Biomed Environ Sci 24: 523-529.
53. Martinez X, Li X, Kovarik J, Klein M, Lambert PH, et al. (1999) Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur J Immunol 29: 3390-3400.
54. Corsi K, Chellat F, Yahia L, Fernandes JC (2003) Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 24: 1255-1264.
55. Wolfert MA, Seymour LW (1996) Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA. Gene Ther 3: 269-273.
56. Xu J, Dai W, Wang Z, Chen B, Li Z, et al. (2011) Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol 18: 75-81.
57. Cripps AW, Kyd JM (2007) Comparison of mucosal and parenteral immunisation in two animal models of pneumococcal infection: otitis media and acute pneumonia. Vaccine 25: 2471-2477.
58. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484.
59. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, et al. (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 92: 128-140.
60. Mohanan D, Slutter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, et al. (2010) Administration routes affect the quality of immune responses: A crosssectional evaluation of particulate antigen-delivery systems. J Control Release 147: 342-349.
61. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A (1995) The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 182: 1579-1584.
62. Mazumder S, Maji M, Das A, Ali N (2011) Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One 6: e14644.
63. Tebbey PW, Scheuer CA, Peek JA, Zhu D, LaPierre NA, et al. (2000) Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18: 2723-2734.
64. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, et al. (2000) A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19: 1188-1198.
65. Liang R, van den Hurk JV, Babiuk LA, van Drunen Littel-van den Hurk S, Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from Bovine viral diarrhea virus in cattle (2006) J Gen Virol 87: 2971-2982.
66. Toussaint JF, Letellier C, Paquet D, Dispas M, Kerkhofs P (2005) Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1. Vaccine 23: 5073-5081.
67. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, et al. (2003) Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21: 1478-1485.